Expertise in
1
conditions

Juan A. Virizuela

Complejo Hospitalario Universitario De Santiago
Santiago De Compostela, GA, ES 
Expertise in
1
conditions
Complejo Hospitalario Universitario De Santiago
Santiago De Compostela, GA, ES 

Overview

Juan Virizuela practices practicing medicine in Santiago De Compostela, Spain.

Mr. Virizuela is highly rated in 1 condition, according to our data. His clinical expertise encompasses Febrile Neutropenia, Breast Cancer, Bladder Cancer, and Urothelial Cancer.

He is actively involved in clinical research, co-authoring 44 peer reviewed articles and participating in 8 clinical trials.

Gender

Male

Locations

Complejo Hospitalario Universitario de Santiago
Santiago De Compostela, GA, Spain

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

8 Clinical Trials

Phase II Non Randomized Clinical Trial of NIVOLUMAB/IPILIMUMAB Maintenance Following First-line Chemotherapy in Unresectable Locally Advanced or Metastatic Urothelial Cancer.
Phase II Non Randomized Clinical Trial of NIVOLUMAB/IPILIMUMAB Maintenance Following First-line Chemotherapy in Unresectable Locally Advanced or Metastatic Urothelial Cancer.
Enrollment Status: Completed
Publish Date: April 24, 2026
Intervention Type: Drug
Study Drugs: Nivolumab, Ipilimumab
Study Phase: Phase 2
A Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti-HER2 Therapy + Endocrine Therapy vs. Anti-HER2 Therapy + Endocrine Therapy After Induction Treatment for Hormone Receptor Positive (HR+)/HER2-Positive Metastatic Breast Cancer
A Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti-HER2 Therapy + Endocrine Therapy vs. Anti-HER2 Therapy + Endocrine Therapy After Induction Treatment for Hormone Receptor Positive (HR+)/HER2-Positive Metastatic Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: February 12, 2026
Intervention Type: Drug
Study Drugs: Palbociclib, Trastuzumab, Pertuzumab, Letrozole, Anastrozole, Exemestane, Fulvestrant
Study Phase: Phase 3
A Study Evaluating the Pregnancy Outcomes and Safety of Interrupting Endocrine Therapy for Young Women With Endocrine Responsive Breast Cancer Who Desire Pregnancy
A Study Evaluating the Pregnancy Outcomes and Safety of Interrupting Endocrine Therapy for Young Women With Endocrine Responsive Breast Cancer Who Desire Pregnancy
Enrollment Status: Active_not_recruiting
Publish Date: February 09, 2026
Intervention Type: Other
Study Phase: Not Applicable
A Phase II Trial of Palbociclib in Combination With Trastuzumab and Endocrine Therapy in Patients With Previously-treated Locally Advanced or Metastatic HER2-positive Breast Cancer (PATRICIA II)
A Phase II Trial of Palbociclib in Combination With Trastuzumab and Endocrine Therapy in Patients With Previously-treated Locally Advanced or Metastatic HER2-positive Breast Cancer (PATRICIA II)
Enrollment Status: Completed
Publish Date: April 18, 2024
Intervention Type: Drug
Study Drugs: Palbociclib, Trastuzumab, Endocrine therapy, Chemotherapy, Antibody-Drug Conjugates
Study Phase: Phase 2
A Randomized, Double-Blind, Placebo-Controlled Phase 2 Clinical Trial Comparing CB-839 in Combination With Cabozantinib (CB-Cabo) vs. Placebo With Cabozantinib (Pbo-Cabo) in Patients With Advanced or Metastatic Renal Cell Carcinoma (RCC)
A Randomized, Double-Blind, Placebo-Controlled Phase 2 Clinical Trial Comparing CB-839 in Combination With Cabozantinib (CB-Cabo) vs. Placebo With Cabozantinib (Pbo-Cabo) in Patients With Advanced or Metastatic Renal Cell Carcinoma (RCC)
Enrollment Status: Completed
Publish Date: March 20, 2023
Intervention Type: Drug
Study Drugs: CB-839, Cabozantinib
Study Phase: Phase 2
A Multi-arm, Multi-stage, Randomized Phase II/III Trial of Immunotherapy Strategies in Metastatic Hormone-sensitive Prostate Cancer
A Multi-arm, Multi-stage, Randomized Phase II/III Trial of Immunotherapy Strategies in Metastatic Hormone-sensitive Prostate Cancer
Enrollment Status: Unknown
Publish Date: October 26, 2022
Intervention Type: Drug
Study Drugs: Ipilimumab, Nivolumab, Docetaxel, ADT
Study Phase: Phase 2/Phase 3
Impact of the Combination of Durvalumab (MEDI4736) Plus Olaparib (AZD2281) Administered Prior to Surgery in the Molecular Profile of Resectable Urothelial Bladder Cancer.
Impact of the Combination of Durvalumab (MEDI4736) Plus Olaparib (AZD2281) Administered Prior to Surgery in the Molecular Profile of Resectable Urothelial Bladder Cancer.
Enrollment Status: Completed
Publish Date: April 06, 2020
Intervention Type: Drug
Study Phase: Phase 2
Randomized, Open-label, Three-arm, Parallel, Phase 0 Study of Metronomic Oral Vinorelbine and Letrozole Versus Letrozole or Vinorelbine Alone in Post-menopausal Women With Hormone Receptor-positive HER2-negative Early Breast Cancer
Randomized, Open-label, Three-arm, Parallel, Phase 0 Study of Metronomic Oral Vinorelbine and Letrozole Versus Letrozole or Vinorelbine Alone in Post-menopausal Women With Hormone Receptor-positive HER2-negative Early Breast Cancer
Enrollment Status: Completed
Publish Date: September 20, 2018
Intervention Type: Drug
Study Phase: Early Phase 1
View 7 Less Clinical Trials

44 Total Publications

Pembrolizumab and Paclitaxel in HR+/HER2- Breast Cancer with HER2-Enriched or Basal-Like Subtypes.
Pembrolizumab and Paclitaxel in HR+/HER2- Breast Cancer with HER2-Enriched or Basal-Like Subtypes.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: July 11, 2025

Frequently Asked Questions about Juan A. Virizuela

Is Juan A. Virizuela a top-rated expert for Febrile Neutropenia?

MediFind is an objective health platform that identifies experts based on real-world data. Juan A. Virizuela is classified as an Advanced expert for Febrile Neutropenia, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Juan A. Virizuela participate in research or clinical trials?

Yes. Juan A. Virizuela has published 44 articles and abstracts on conditions like Febrile Neutropenia. You can view a list of Juan A. Virizuela's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Virizuela's expertise for a condition
ConditionClose
      View All 7 Experienced Conditions
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile